Prostate cancer news reports: Sunday, December 6, 2009

In today’s news reports we comment on:

  • The possible link between obesity and prostate cancer risk
  • The economic impact of widespread prostate cancer screening in Europe
  • The potential roles of tumor volume and PSMs in projecting need for adjuvant radiotherapy post-surgery
  • Biochemical progression after treatment with degarelix (at up to 1 year) … READ MORE …

Does control of S-ALP imply control of bone mets with degarelix?

Before the coming of the PSA test, urologists used to use serum acid phosphatase levels (usually) and serum alkaline phosphatase (S-ALP) levels (less commonly) to assess the status of men at risk for or under treatment for metastatic prostate cancer. … READ MORE …

Prostate cancer news reports: Wednesday, August 5, 2009

Apparently Ferring Pharmaceuticals has finally been able to get Firmagon® approved as the new trade (brand) name for degarelix (their new LHRH antagonist) here in the USA. This is the same brand name as is used in Europe. Who knows why it took so long! The media release doesn’t say.

In other news reports today we comment on studies dealing with:

  • Vitamin B-6 and prostate cancer-specific survival
  • Tallness and prostate cancer risk
  • Quality of care indicators for prostate cancer studies … READ MORE …

Understanding the potential of degarelix (and the risks)

A review article and three different sets of editorial comments have just been published in Oncology. They lay out the opinions of several specialists on the potential uses of degarelix — a recently approved, “second-generation” LHRH antagonist — in the management of prostate cancer. All the relevant articles are available in full on line. … READ MORE …

Phase III trial of intermittent degarelix therapy to be started

Ferring Pharmaceuticals has announced the company’s intent to initiate a randomized, controlled, multi-center trial of degarelix used as intermittent androgen deprivation therapy (IADT) in patients with advanced prostate cancer who have rising serum PSA levels after previous curative therapies. … READ MORE …

The Thursday news report: March 5, 2009

There are a significant number of relatively long-term news items in today’s report. Of most immediate interest to the majority of prostate cancer patients and educators we include reports on:

  • The fact that over 70 percent of cancers thought to be unilateral at biopsy turn out to be bilateral post-surgery (which has implications for focal therapy)
  • The availability of degarelix for actual prescription and clinical use in the USA
  • The formation of a specialized new urologic oncology research institute at UCLA … READ MORE …

Degarelix receives final approval for marketing in Europe

We reported last December that the Committee for Medicinal Products for Human Use had adopted a positive opinion and had recommended marketing authorization for degarelix, a second-generation LHRH receptor antagonist, for the treatment of patients with advanced, hormone-dependent prostate cancer.

According to a media release from Ferring Pharmaceuticals earlier today, the European Union has now finalized approval of degarelix for clinical use in Europe.